''Threefold dual'' copper homeostasis regulation strategy: Targeted copper surge for enhanced cancer immunotherapy
5 affiliations
- 1Department of Medical Imaging, Shanxi Medical University, Taiyuan, 030001, PR China; Department of Radiology, Fifth Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Taiyuan, 030000, PR China
- 2Department of Radiology, Fifth Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Taiyuan, 030000, PR China
- 3School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, 030001, PR China
- 4Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, PR China; Corresponding author.
- 5Department of Radiology, Fifth Hospital of Shanxi Medical University, Shanxi Provincial People's Hospital, Taiyuan, 030000, PR China; Corresponding author.
Abstract
Copper-based therapeutics disrupting intracellular copper homeostasis hold immense promise for cancer immunotherapy, yet their efficacy is severely limited by inadequate copper accumulation, intratumoral antioxidant defenses, and nonspecific drug release. To surmount these limitations, we engineered CuTF-DC_AC50, an innovative copper homeostasis nanomodulator implementing a ''threefold dual'' strategy to maximize therapeutic outcomes. Specifically, the nanomodulator drives massive copper overload through a dual-channel influx and efflux regulation mechanism, concurrently delivering exogenous Cu 2+ and inhibiting ATOX1-mediated copper efflux via its DC_AC50 component. Simultaneously, it dismantles the intracellular antioxidant barrier through dual-mechanism glutathione (GSH) depletion, mediated by disulfide bond cleavage within the TPH scaffold alongside Cu 2+ reduction. Furthermore, CuTF-DC_AC50 undergoes dual-responsive degradation triggered by the acidic and GSH-abundant tumor microenvironment (TME), enabling precise drug release and spatial-temporal orchestration of the therapeutic cascade. This targeted copper surge synergistically triggers cuproptosis and pyroptosis, thereby robustly activating immunogenic cell death (ICD). Consequently, in vivo investigations demonstrate that this nanomodulator profoundly remodels the immunosuppressive TME, promotes robust immune cell infiltration, and substantially suppresses tumor growth. By exploiting the CuTF-DC_AC50-induced PD-L1 upregulation, its combination with αPD-L1 markedly amplifies therapeutic efficacy in CT26 tumor-bearing mice, establishing a highly programmable and clinically translatable combinatorial strategy for potentiated cancer immunotherapy.
Related
- PARP1 and PD-L1 dual-targeted bifunctional small-molecule inhibitors: a novel strategy for dual immunotherapy of triple-negative breast cancer
- Extracellular redox regulation in Pacific oyster mucosal immunity and microbiota homeostasis
- Targeted tumor desialylation by engineered probiotic reprograms the tumor microenvironment to potentiate immunotherapy
- A Vma13-targeted thiadiazole-succinimide disrupts V-ATPase dependent arginine-polyamine homeostasis to block Candida albicans escape from macrophages
- Gcn5 and mTORC1 mediated regulation of autophagy controls Drosophila blood cell homeostasis
BibTeX
@article{wang2026threefold,
title = {{''Threefold dual'' copper homeostasis regulation strategy: Targeted copper surge for enhanced cancer immunotherapy}},
author = {Qian Wang and Qian Wang and Jie Dong and Yuxin Zhou and Zichen Cui and Baole Li and Botao Qu and Ruiping Zhang},
journal = {Materials Today Bio},
year = {2026},
month = oct,
doi = {10.1016/j.mtbio.2026.103795},
url = {https://doi.org/10.1016/j.mtbio.2026.103795},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - ''Threefold dual'' copper homeostasis regulation strategy: Targeted copper surge for enhanced cancer immunotherapy
AU - Qian Wang
AU - Qian Wang
AU - Jie Dong
AU - Yuxin Zhou
AU - Zichen Cui
AU - Baole Li
AU - Botao Qu
AU - Ruiping Zhang
PY - 2026
DA - 2026/10/29
JO - Materials Today Bio
DO - 10.1016/j.mtbio.2026.103795
UR - https://doi.org/10.1016/j.mtbio.2026.103795
AB - Copper-based therapeutics disrupting intracellular copper homeostasis hold immense promise for cancer immunotherapy, yet their efficacy is severely limited by inadequate copper accumulation, intratumoral antioxidant defenses, and nonspecific drug release. To surmount these limitations, we engineered CuTF-DC_AC50, an innovative copper homeostasis nanomodulator implementing a ''threefold dual'' strategy to maximize therapeutic outcomes. Specifically, the nanomodulator drives massive copper overload through a dual-channel influx and efflux regulation mechanism, concurrently delivering exogenous Cu 2+ and inhibiting ATOX1-mediated copper efflux via its DC_AC50 component. Simultaneously, it dismantles the intracellular antioxidant barrier through dual-mechanism glutathione (GSH) depletion, mediated by disulfide bond cleavage within the TPH scaffold alongside Cu 2+ reduction. Furthermore, CuTF-DC_AC50 undergoes dual-responsive degradation triggered by the acidic and GSH-abundant tumor microenvironment (TME), enabling precise drug release and spatial-temporal orchestration of the therapeutic cascade. This targeted copper surge synergistically triggers cuproptosis and pyroptosis, thereby robustly activating immunogenic cell death (ICD). Consequently, in vivo investigations demonstrate that this nanomodulator profoundly remodels the immunosuppressive TME, promotes robust immune cell infiltration, and substantially suppresses tumor growth. By exploiting the CuTF-DC_AC50-induced PD-L1 upregulation, its combination with αPD-L1 markedly amplifies therapeutic efficacy in CT26 tumor-bearing mice, establishing a highly programmable and clinically translatable combinatorial strategy for potentiated cancer immunotherapy.
SN - 2590-0064
ER -